Methylnaltrexone Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Constipation - Chronic

Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain:
12 mg subcutaneously once a day

Comments: Prior to initiation, discontinue all maintenance laxative therapy; laxatives can be used as needed for suboptimal response after 3 days.

Opioid-Induced Constipation in Patients with Advanced Illness:
-One-dose subcutaneously every other day as needed, but no more frequently than 1 dose in a 24-hour period; weight-based dosing as follows:
Less than 38 kg: 0.15 mg/kg
38 kg to less than 62 kg: 8 mg (0.4 mL)
62 kg to 114 kg: 12 mg subcutaneously (0.6 mL)
More than 114 kg: 0.15 mg/kg subcutaneously

Comments: To determine injection volume for patients whose weight is less than 38 kg or more than 114 kg: multiply patient weight (kg) by 0.0075 and round up to the nearest 0.1 mL

Uses:
-For the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
-For the treatment of opioid-induced constipation in adult patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient.

Renal Dose Adjustments

-CrCl 30 to 80 mL/min: No adjustment recommended
-CrCl less than 30 mL/min: Reduce dose by one-half

Liver Dose Adjustments

Mild or moderate hepatic impairment: No adjustment recommended
Severe hepatic impairment: Data not available

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-For subcutaneous injection only; do not administer more than 1 dose in a 24-hour period
-Rotation of injection sites is recommended; suggested injection sites are upper legs, abdomen and upper arms
-Once administered, be within close proximity to toilet facilities

Storage requirements:
-Store at room temperature, do not freeze
-If drug has been drawn into a syringe, stable at room temperature for up to 24 hours
-Protect from light

Reconstitution/preparation techniques: See product information.

General:
-If treatment with opioid pain medication is discontinued, this drug should be discontinued; if opioid regimen is change, re-evaluate continued need of this drug.
-In clinical trials in patients with advanced illness, this drug was administered concomitantly with a laxative regimen.
-In patients with chronic non-cancer pain, all maintenance laxative therapy should be discontinued prior to initiating therapy; laxatives can be used as needed after 3 days.
-This drug has been shown to be efficacious in patients who have taken opioids for at least 4 weeks; sustained exposure to opioids prior to starting this drug may increase the patient's sensitivity to this drug.

Monitoring:
-Monitor for the development of severe, persistent, or worsening abdominal pain; discontinue therapy if this occurs.

Patient advice:
-Be within close proximity to toilet facilities once the drug is given.
-If unusually severe, persistent, or worsening abdominal pain develops, promptly seek medical attention.
-If severe or persistent diarrhea occurs, patients should be advised to stop therapy and consult their healthcare provider.
-If symptoms of opioid withdrawal such as sweating, chills, anxiety, irritability, and yawning occur, patients should be instructed to let their healthcare provider know.
-Speak to your physician or health care professional if you become pregnant, intend to become pregnant, or are breastfeeding.

Hide
(web1)